Eltrombopag

Drugs

Volumn 69, Issue 5, 2009, Pages 567-576

  Garnock Jones, Karly P ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ELTROMBOPAG; IMMUNOGLOBULIN; JANUS KINASE; PLACEBO; STAT PROTEIN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLEEDING; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MEGAKARYOCYTE; MENORRHAGIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; STEM CELL; THROMBOCYTE COUNT; THROMBOCYTE MEMBRANE; VOMITING; WORLD HEALTH ORGANIZATION;

BENZOIC ACIDS; CLINICAL TRIALS AS TOPIC; HUMANS; HYDRAZINES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, THROMBOPOIETIN;

EID: 64949105186     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969050-00005     Document Type: Article

References (29)

1. Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol Oncol Clin North Am 2007; 21 (4): 743-59
2. Provan D, Newland A, Norfolk D, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 574-96
3. Feudjo-Tepie MA, Robinson NJ, Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal [letter]. J Thromb Haemost 2008 Apr; 6 (4): 711-2
4. George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006; 4 (8): 1664-72
5. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68 (7): 901-12
6. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematol-ogy. Blood 1996; 88 (1): 3-40
7. Rodeghiero F. First-line therapies for immune thrombocy-topenic purpura: re-evaluating the need to treat. Eur J Haematol 2008; 80 Suppl. 69: 19-26
8. Newland A. Thrombopoietin mimetic agents in the man-agement of immune thrombocytopenic purpura. Semin Hematol 2007 Oct; 44 (4 Suppl. 5): S35-45
9. Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietin receptor agonist. Stem Cells 2009; 27: 424-30
10. Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro [abstract no. 3888]. Blood 2004; 104 (11): 59b
11. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007 Jun 1; 109 (11): 4739-41
12. Psaila B, Bussel JB, Linden MD, et al. In vivo effects of eltrombopag on human platelet function [abstract no. 1301]. Blood 2007 Nov 1; 110 (11): 391-2
13. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007 Nov 29; 357 (22): 2237-47
14. Bussel J, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009 Feb 21; 373 (9664): 641-8
15. GlaxoSmithKline. Promacta (eltrombopag tablets): US prescribing information. [online]. Available from URL: http://www.promactacares.com/ prescribing-information.pdf [Accessed 2008 Nov 24]
16. Bussel J, Psaila B, Saleh M, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura [abstract no. 3431]. Blood 2008; 112(11): 1176
17. Bussel J, Cheng G, Saleh M, et al. Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura [abstract no. 3432]. Blood 2008 Nov 16; 112 (11): 1177. Plus poster presented at the 50th annual meeting of the American Society of He-matology; 2008 Dec 6-9; San Francisco (CA)
18. Cheng G, Saleh M, Bussel J, et al. Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a phase III, double-blind, placebo-controlled study (RAISE) [abstract no. 400]. Blood 2008; 112 (11). Plus oral presentation at the 50th annual meeting of the American Society of Hematol-ogy; 2008 Dec 6-9; San Francisco (CA)
19. Bussel J, Newland A, Provan A, et al. Severe bleeding in patients with severe chronic ITP: results from two double-blind, placebo-controlled, randomized clinical trials [abstract no. 0758]. Haematologica 2007; 92 Suppl. 1: 282
20. Saleh MN, Bussel JB, Stone N, et al. Oral eltrombopag increases platelet counts and reduces bleeding in chronic ITP patients: pooled results of phase II and phase III trials [poster]. 13th Annual Congress of the European Hema-tology Association; 2008 Jun 12-15; Copenhagen
21. Newland A, Bussel JB, Stone N, et al. Eltrombopag effectively elevates platelets in patients with chronic idiopathic thrombocytopenic purpura (ITP) regardless of splenectomy status [poster]. 13th Annual Congress of the European Hematology Association; 2008 Jun 12-15; Copenhagen
22. Cheng G. Platelet counts remain elevated in two patients with idiopathic thrombocytopenic purpura after cessation of oral eltrombopag [abstract no. 3927]. Blood 2007; 110 (11): 49b
23. Psaila B, Bussel JB, Vasey S, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura [abstract no. 0294]. Haematologica 2008; 93 Suppl. 1: 120. Plus poster presented at the 13th Annual Congress of the European Hematology Association; 2008 Jun 12-15; Copenhagen
24. Bussel JB, McHutchison J, Provan D, et al. Safety of eltrombopag, an oral non-peptide platelet growth factor, in the treatment of thrombocytopenia: results of four randomized, placebo-controlled studies [abstract no. 1299]. Blood 2007; 110 (11): 391a
25. GlaxoSmithKline. PROMACTA(R) (eltrombopag) receives unanimous recommendation by FDA advisory panel [media release]. 2008 May 30
26. GlaxoSmithKline. Eltrombopag to reduce the need for platelet transfusion in subjects with chronic liver disease and thrombocytopenia undergoing elective invasive procedures [ClinicalTrials.gov identifier NCT00678587]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Mar 26]
27. GlaxoSmithKline. Eltrombopag to initiate and maintain interferon antiviral treatment to subjects with hepatitis C related liver disease [ClinicalTrials.gov identifier NCT00516321]. US National Institutes of Health, Clin-icalTrials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2009 Mar 26]
28. GlaxoSmithKline. Eltrombopag to initiate and maintain interferon antiviral treatment to benefit subjects with hepatitis C liver disease [ClinicalTrials.gov identifier NCT00529568]. US National Institutes of Health, Clin-icalTrials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2009 Mar 26]
29. Baranwal A, Fraser L, Jayawardene D, et al. Efficacy and safety of eltrombopag, a novel, oral, platelet growth factor on platelet counts in patients with cancer receiving carboplatin/paclitaxel [abstract no. P-168]. Support Care Cancer 2007; 15:761